Markey Cancer Center

Search Clinical Trials

Choose age group:

Protocols

Trials Open: 12
Cancer Type: Kidney
Protocol No. Title
ATRIUM-ICI-M1201 ATRIUM-ICI-M1201: AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
MCC-16-MULTI-18-PMC Genomic Testing for Patients with Refractory Cancer to Determine Treatment
MCC-16-MULTI-19-PMC Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
MCC-17-MTB-01-PMC MCC-17-MTB-01-PMC: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
MCC-20-MULTI-34 Tobacco Treatment Optimization and Preferences during Concurrent Cancer Treatment (TTOP)
MCC-22-64346 MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study)
MCC-23-MULTI-61 Comprehensive Connected Cancer Care (C4): Intervention Evaluation
NCI-CIRB-A031704 Nivolumab+Ipilimumab with Nivolumab vs. Cabozantinib+Nivolumab in Metastatic Untreated RCC
NCI-CIRB-APEC14B1 Project:EveryChild
NCI-CIRB-AREN1921 NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
NCI-CIRB-EAY191-E5-MATCH-PMC Testing the Use of AMG 510 and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor
NCI-CIRB-EAY191-N5-MATCH-PMC NCI-CIRB-EAY191-N5-MATCH-PMC: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors, A ComboMATCH Treatment Trial

Protocols

Trials Open: 12
Cancer Type: Kidney
Protocol No. Title
ATRIUM-ICI-M1201 ATRIUM-ICI-M1201: AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
MCC-16-MULTI-18-PMC Genomic Testing for Patients with Refractory Cancer to Determine Treatment
MCC-16-MULTI-19-PMC Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
MCC-17-MTB-01-PMC MCC-17-MTB-01-PMC: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
MCC-20-MULTI-34 Tobacco Treatment Optimization and Preferences during Concurrent Cancer Treatment (TTOP)
MCC-22-64346 MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study)
MCC-23-MULTI-61 Comprehensive Connected Cancer Care (C4): Intervention Evaluation
NCI-CIRB-A031704 Nivolumab+Ipilimumab with Nivolumab vs. Cabozantinib+Nivolumab in Metastatic Untreated RCC
NCI-CIRB-APEC14B1 Project:EveryChild
NCI-CIRB-AREN1921 NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
NCI-CIRB-EAY191-E5-MATCH-PMC Testing the Use of AMG 510 and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor
NCI-CIRB-EAY191-N5-MATCH-PMC NCI-CIRB-EAY191-N5-MATCH-PMC: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors, A ComboMATCH Treatment Trial

Protocols

Trials Open: 3
Cancer Type: Kidney
Protocol No. Title
MCC-22-64346 MCC-22-64346: Local Flavor Policies to Enhance Equity in Tobacco (REACT Study)
NCI-CIRB-APEC14B1 Project:EveryChild
NCI-CIRB-AREN1921 NCI-CIRB-AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy